NCT03623373 2026-03-30
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 2 Completed
Clinical Trials
8 trialsNCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
NCT02296918 2025-12-19
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Acerta Pharma BV
Phase 1 Completed
NCT02362035 2025-12-11
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
NCT02328014 2025-12-09
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Acerta Pharma BV
Phase 1/2 Completed
NCT04008706 2025-12-01
ASSURE
AstraZeneca
Phase 3 Completed
NCT04883749 2025-06-08
CLL-Frail
German CLL Study Group
Phase 2 Completed
NCT04402138 2025-05-13
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed